文献速递肾小球疾病

低剂量环磷酰胺联合糖皮质激素治疗原发性膜性肾病的随机对照试验

Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2025-08-21

该随机对照试验纳入114例原发性膜性肾病患者,比较低剂量与标准剂量环磷酰胺/糖皮质激素的疗效。意向性分析显示低剂量组78.94%、标准剂量组87.71%达到主要结局(治疗差异-8.78%,97.5%CI下限-22%),满足非劣效性(P=0.009)。低剂量组不良事件发生率更低(78.94% vs 96.49%)。

要点

  • 低剂量环磷酰胺/激素在蛋白尿缓解上非劣效于标准剂量。
  • 低剂量组不良事件发生率更低。
  • 需注意非劣效界值及随访时间限制。

核心结论

  • 低剂量环磷酰胺/糖皮质激素在诱导原发性膜性肾病蛋白尿缓解方面可能不劣于标准剂量。

研究设计与样本

  • 随机对照试验,纳入114例原发性膜性肾病患者,每组57例。

主要发现

  • 意向性分析中,低剂量组45例(78.94%)和标准剂量组50例(87.71%)达到主要结局(治疗差异-8.78%,97.5%CI下限-22%),满足非劣效性(P=0.009)。
  • 低剂量组45例(78.94%)和标准剂量组55例(96.49%)发生至少1次不良事件(差异-17.54%,97.5%CI下限-29.1%)。

关键数值与推荐

  • 低剂量方案:泼尼松龙0.5 mg/kg/d(第1、3、5月)联合口服环磷酰胺1.0-1.5 mg/kg/d(第2、4、6月)。
  • 标准剂量方案:甲泼尼龙1 g/d用3天,继以泼尼松龙0.5 mg/kg/d(第1、3、5月)联合口服环磷酰胺2.0-2.5 mg/kg/d(第2、4、6月)。
  • 主要结局为第6至24个月间蛋白尿完全缓解或部分缓解。

临床怎么用

  • 对于原发性膜性肾病患者,可考虑使用低剂量环磷酰胺/糖皮质激素方案以减少不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The use of cyclophosphamide with corticosteroids for the management of membranous nephropathy (MN) is associated with significant safety concerns. Several retrospective studies suggest that a lower dose may effectively induce remission in participants with MN. This randomized trial assessed whether the lower dose of cyclical cyclophosphamide/corticosteroids was noninferior to the standard dose in patients with MN. METHODS: We randomly assigned 114 participants (32 women and 82 men) to receive either the low dose (prednisolone, 0.5 mg/kg/d during months 1, 3, and 5 along with oral cyclophosphamide, 1.0-1.5 mg/kg/d during months 2, 4, and 6) or the standard-dose cyclophosphamide/corticosteroids (methylprednisolone, 1 g/d for 3 days, followed by prednisolone, 0.5 mg/kg/d during months 1, 3, and 5, along with oral cyclophosphamide, 2.0-2.5 mg/kg/d during months 2, 4, and 6). The primary outcome was complete remission (CR) or partial remission (PR) of proteinuria between months 6 and 24. RESULTS: A total of 57 participants were randomized into each group. The mean age was 41.53 ± 12.29 years; median proteinuria, mean serum albumin, and creatinine levels were respectively 6.83 g/d (interquartile range: 5.02-10.15), 2.34 ± 0.58 g/dl, and 0.92 ± 0.26 mg/dl and were comparable between groups. In the intention-to-treat (ITT) analysis, 45 participants (78.94%) in the low-dose group and 50 participants (87.71%) in the standard-dose group achieved the primary outcome (treatment difference: -8.78%, 97.5% confidence interval [CI]: lower limit -22%) and met the criteria for noninferiority (P = 0.009). Forty-five (78.94%) and 55 (96.49%) participants receiving the low-dose and standard-dose cyclophosphamide/corticosteroids, respectively, experienced at least 1 adverse event (difference: -17.54%, 97.5% CI: lower limit -29.1%). CONCLUSION: The results suggest that low-dose cyclophosphamide/corticosteroids may be as effective as the standard dose of cyclical cyclophosphamide/corticosteroids in achieving proteinuria remission in MN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ramachandran R, Chauhan P, Bharati J, et al. Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy. Kidney Int Rep. 2025. PMID: 41278314. doi:10.1016/j.ekir.2025.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。